Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Borken – page 16

1 431 clinical trials in Borken, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Borken at a glance
1 431
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 431 trials in Borken

Open in trial search

A study to evaluate the effect of EA-230 on the hospital stay length for patients undergoing coronary artery bypass surgery for coronary artery disease.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:EA-230
  • Sponsor:EBI Anti Sepsis B.V.

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Novartis Pharma AG

A study of PF-08634404, ipilimumab, and axitinib in adults with advanced or metastatic kidney cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Pfizer Inc.

Colon cancer

Recruiting

A study to evaluate the safety and effectiveness of darizmetinib hydrochloride in patients who have had liver surgery due to colon cancer metastases

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Darizmetinib hydrochloride
  • Sponsor:HepaRegeniX GmbH

Bladder cancer

Recruiting

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Neoplasm malignant+1

Recruiting

A Phase I/II Study of GVV858 Alone or in Drug Combination for Patients with Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Novartis Pharma AG

Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Breast cancer+1

Recruiting

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Phase 2 Study of Rinatabart Sesutecan with Pegfilgrastim in Adults with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Crohn's disease

Recruiting

An observational study on the use of methotrexate in children and adolescents with Crohn's disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Methotrexate
  • Sponsor:Amsterdam UMC Stichting

Obesity+1

Recruiting

A study to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight and type 2 diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Borken

What the registry says about research in the country

01 Neuropathic Pain Research

Investigating innovative treatments for patients with diabetic polyneuropathy, focusing on new therapeutic approaches for chronic pain management.

  • Diabetic Neuropathy
  • Pain Management
  • Treatment Efficacy

Clinical evaluations of add-on treatments aim to improve quality of life for patients with chronic neuropathic conditions.

02 Trauma-Related Neuropathy

Studies examining treatment options for post-operative and traumatic peripheral neuropathy, with emphasis on chronic pain relief strategies.

  • Post-Surgical Pain
  • Trauma-Induced Neuropathy
  • Pain Relief Solutions

Research focused on developing effective therapeutic interventions for trauma-related chronic pain conditions.

03 Central Neuropathy Studies

Comprehensive research into central neuropathy of various origins, evaluating novel treatment approaches for chronic pain management.

  • Central Nervous System
  • Pain Treatment
  • Therapeutic Efficacy

Advanced clinical trials exploring innovative solutions for central nervous system-related pain conditions.

04 Chronic Back Pain Treatment

Investigation of new therapeutic approaches for managing chronic back pain, focusing on treatment tolerability and effectiveness.

  • Back Pain Management
  • Pain Relief
  • Treatment Outcomes

Studies aimed at improving treatment options for patients suffering from persistent back pain conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.